Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
UnknownNCT06270433
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder
This study evaluates the safety and effectiveness of Toludesvenlafaxine hydrochloride sustained-release tablets for people with depression.
Medication studyAges 18–65China
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Toludesvenlafaxine hydrochloride sustained-release tablets for people with depression.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Nanjing, ChinaSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 19, 2024
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 80
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06270433
- Official title
Show the full official title
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial
Recruitment & locations
Status unknownNanjing
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Toludesvenlafaxine hydrochloride sustained-release tablets for people with depression.
Who is behind this study?
The study sponsor is Jiangsu Province Nanjing Brain Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Toludesvenlafaxine hydrochloride sustained-release tablets and Desvenlafaxine succinate sustained-release tablets.
Who can participate?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
UnknownNCT05599126
Mianserin in Combination With SSRIs in Depression With Sleep Problems
This study evaluates the effectiveness of Mianserin for people with depression.
UnknownNCT06358014
Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen
China
UnknownNCT05945342
Development and Application of Comprehensive Intervention Techniques for Adolescent Depression
China